Chemical Structure (Norliquid 01)
Norliqva Solution
Product Images NDC 46287-035
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Norliqva (NDC 46287-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cmp Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)
Figure 2 – Effects On Primary Endpoint Of Amlodipine Versus Placebo Across Sub-groups (Norliquid 03)
This is a table of clinical trial results for a medication called Amlodipine compared to a placebo. The table shows the number of patients in different categories according to age, gender, baseline sitting SBP, baseline vessel disease, baseline vessels with stenosis, and PCI-stent strategies. It also shows the Hazard Ratio (with 95% Confidence Interval) for each group.*
Principal Display Panel (150 mL Bottle Label)
Norligva is an oral solution medication containing 1mg of amlodipine besylate per mL. The recommended dosage is provided in the prescribing information. The medication contains 4% alcohol and should be stored between 20°C to 25°C. Children should not have access to Norligva, and it should not be dispensed to patients outside of the original packaging. It is distributed by CMP Pharma, Inc., and has an NDC number of 46267-035-15.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
